Trial Profile
A phase II study of docetaxel plus ramcirumab with pegfilgrastim in treated patients with advanced non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2019
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pegfilgrastim (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 27 Dec 2018 Status changed from recruiting to discontinued.
- 09 May 2017 New trial record